EOVIST Dosage & Rx Info | Uses, Side Effects

Eovist Generic Name & Formulations

Legal Class

General Description

Gadoxetate disodium 181.43mg/mL (0.25mmol/mL); soln for IV inj; preservative-free.

Pharmacological Class

Gadolinium-based contrast agent.

How Supplied

Single-dose vials (10mL, 15mL)—5

Storage

Store at temperatures between 20° to 25° C (68° to 77° F); excursions permitted to 15° to 30° C (59° to 86°F).

Manufacturer

Bayer Corporation

Generic Availability

Mechanism of Action

Gadoxetate disodium is a paramagnetic compound and develops a magnetic moment when placed in a magnetic field. The relatively large magnetic moment produced by gadoxetate disodium results in a local magnetic field, yielding enhanced relaxation rates (shortening of relaxation times) of water protons in the vicinity of the paramagnetic agent, which leads to an increase in signal intensity (brightening) of blood and tissue.

Eovist Indications

Indications

For use in MRI of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.

Eovist Dosage and Administration

Adults and Children

Premature infants: not established. Give as IV bolus inj at a rate of ~2mL/sec. 0.1mL/kg (0.025mmol/kg); flush IV cannula with normal saline after inj. See full labeling re: imaging guidelines.

Eovist Contraindications

Not Applicable

Eovist Boxed Warnings

Boxed Warning

Risk associated with intrathecal use. Nephrogenic systemic fibrosis.

Eovist Warnings/Precautions

Warnings/Precautions

Not approved for intrathecal use. Increased risk of nephrogenic systemic fibrosis in chronic kidney disease or acute kidney injury; avoid use. Screen for renal dysfunction. Do not exceed recommended dose and allow sufficient time for drug elimination before re-administration. Have emergency resuscitative equipment available. History of asthma or other allergic disorders. Monitor for hypersensitivity reactions during and after administration. Increased risk of gadolinium retention with multiple lifetime doses, in pregnant patients, children, and those with inflammatory conditions; minimize repetitive imaging studies. Elevated bilirubin (>3mg/dL) or ferritin may reduce hepatic contrast effect; perform MRI no later than 60mins following administration. Avoid extravasation. Severe renal or hepatic failure. Elderly. Pregnancy. Nursing mothers: consider interrupting nursing and pumping/discarding breast milk for up to 10hrs after inj.

Eovist Pharmacokinetics

Distribution

Volume of distribution (at steady state): ~0.21 L/kg. Plasma protein bound: <10%.

Elimination

Renal, hepatobiliary. Half-life: 0.91–0.95 hours.

Eovist Interactions

Interactions

Serum iron using complexometric methods may result in falsely high or low values for up to 24hrs.

Eovist Adverse Reactions

Adverse Reactions

Nausea, headache, feeling hot, dizziness, back pain; hypersensitivity reactions.

Eovist Clinical Trials

See Literature

Eovist Note